Impact of complex treatment regimens using physiotherapy and botulinum toxin type A on the quality of life of patients with erythematotelangiectatic rosacea: results of an open, prospective, randomized study

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Background: Rosacea is a common chronic inflammatory skin disease, predominantly affecting the central part of the face. Patients experience a significant decrease in quality of life and self-esteem during exacerbations, which underlines the importance of effective treatment and preventive measures for this dermatosis.

Objective: Evaluation of the impact of complex treatment regimens including physiotherapy and botulinum toxin type A on the quality of life of patients with erythematotelangiectatic rosacea (ETR).

Materials and methods: The study was designed as a single-center, open-label, prospective, randomized trial and was conducted from 2022 to 2025. A total of 117 patients with ETR participated in the study. Group 1 (comparison, n=26) received pulsed dye laser (PDL) therapy, while Group 2 (n=33) received combination therapy using PDL and local dynamic micromassage (LDM). Patients in Group 3 (n=30) received PDL treatment followed by botulinum therapy. Group 4 (n=28) received PDL, LDM, and botulinum therapy. The impact of restorative treatment regimens on the quality of life of patients with ETR was assessed using the dermatological quality of life index (DQLI). Follow-up examinations were conducted at five points: before treatment, 2 weeks, 2, 4, and 6 months after completion of therapy.

Results: The most pronounced positive effect on the quality of life of patients with ETR was demonstrated by the use of a complex regimen including PDL, LDM, and botulinum toxin type A (p<0.001). The positive effects of combination therapy with PDL and LDM and therapy with PDL and botulinum toxin type A on the quality of life of patients with ETR were comparable in the immediate follow-up period (p=0.708), with the latter showing an advantage 2 months after completion of treatment (p<0.001). The use of PDL monotherapy had the least positive effect on the quality of life of patients with ETR.

Conclusion: The obtained results demonstrated the most pronounced and persistent positive impact on the quality of life of patients with ETR after combination treatment with PDL, LDM, and botulinum toxin type A.

About the authors

Aleksandra L. Rodina

Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation

Author for correspondence.
Email: al.rodina@bk.ru
ORCID iD: 0000-0002-3429-6693

Postgraduate Student, Department of Dermatovenereology and Cosmetology

Russian Federation, Moscow

E. V. Gusakova

Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation

Email: al.rodina@bk.ru
ORCID iD: 0000-0002-9711-6178
Russian Federation, Moscow

E. A. Shatokhina

Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation

Email: al.rodina@bk.ru
ORCID iD: 0000-0002-0238-6563
Russian Federation, Moscow

References

  1. Hua N.J., Chen J., Geng R.S.Q., et al. Efficacy of treatments in reducing facial erythema in rosacea: a systematic review. J Cutan Med Surg. 2025;29(1):43–50. https://doi.org/10.1177/12034754241287546
  2. van Zuuren E.J., Arents B.W.M., van der Linden MMD, Vermeulen S, Fedorowicz Z, Tan J. Rosacea: New Concepts in Classification and Treatment. Am J Clin Dermatol. 2021;22(4):457–465. https://doi.org/10.1007/s40257-021-00595-7
  3. Bulbul Baskan E., Akin Belli A. Evaluation of long-term efficacy, safety, and effect on life quality of pulsed dye laser in rosacea patients. J Cosmet Laser Ther. 2019;21(4):185–189. https://doi.org/10.1080/14764172.2018.1502453
  4. Круглова Л.С. Акне и розацеа: клинические проявления, диагностика и лечение. Москва: ГЭОТАР-Медиа, 2021, 20 с. [Kruglova L.S. Acne and rosacea: clinical manifestations, diagnosis and treatment. Moscow: GEOTAR-Media, 2021, 208 p. (In Russ.)]
  5. Егорова О.А. Физиотерапевтические факторы в лечении больных розацеа. Вестник новых медицинских технологий. 2018;25(4):145-154. [Egorova O.A. Physiotherapeutic factors in the treatment of patients with rosacea, Bulletin of new medical technologies. 2018;25(4):145-154. (In Russ.)].
  6. Кругликов И. Локальный динамический микромассаж. Эстетическая медицина. 2012;11:3–8. [Kruglikov I. Local dynamic micromassage. Aesthetic medicine. 2012;11:3–8. (In Russ.)].
  7. Park J.Y., Ahn M.K., Cho E.B., Park E..J, Kim K.H. Dual-Frequency Ultrasound as a New Treatment Modality for Refractory Rosacea: A Retrospective Study. Dermatol Surg. 2018;44(9):1209-1215. https://doi.org/10.1097/DSS.0000000000001552
  8. Schaller M., Almeida L.M.C., Bewley A., et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020;182(5):1269-1276. https://doi.org/10.1111/bjd.18420
  9. D. Meyer-Rogge and I. Kruglikov. Pilot Study into Super-Fractionation Treatment Strategy of Acne and Rosacea, J Cosmet Dermatol Sci Applicat. 2013;3(3):197-202. https://doi.org/10.4236/jcdsa.2013.33030
  10. Kim Y.J., Moon I.J., Lee H.W., et al. The Efficacy and Safety of Dual-Frequency Ultrasound for Improving Skin Hydration and Erythema in Patients with Rosacea and Acne. J Clin Med. 2021;10(4):834. https://doi.org/10.3390/jcm10040834
  11. Вербовая Е.Д., Родина А.Л. Ботулинотерапия в лечении больных розацеа. Медицинский алфавит. 2022;(8):103-106. [Verbovaya E.D., Rodina A.L. Botulinum therapy in treatment of patients with rosacea. Medical alphabet. 2022;(8):103-106. (In Russ.)]. https://doi.org/10.33667/2078-5631-2022-8-103-106
  12. Егорова О.А. Микротоковая терапия и ботулинотерапия у пациентов с эритематозно-телеангиэктатическим подтипом розацеа. Медицинский алфавит. 2020;(6):54-60. [Egorova O.A. Effectiveness of microcurrent therapy and botulinum therapy in patients with erythematous-telangiectatic subtype of rosacea. Medical alphabet. 2020;(6):54-60. (In Russ.)]. https://doi.org/10.33667/2078-5631-2020-6-54-60
  13. Соколова А.В., Фимочкина Г.Р. Комбинация импульсного лазера на красителе, азелаиновой кислоты, ивермектина и ботулинотерапии в лечении пациентов с розацеа. Фарматека. 2024;31(10):76–80. [Sokolova A.V., Fimochkina G.R. Combination of pulsed dye laser, azelaic acid, ivermectin and botulinum therapy in the treatment of patients with rosacea Pharmateca. 2024;31(10):76–80. (In Russ.)]. https://doi.org/10.18565/pharmateca.2024.10.76-80
  14. Al-Niaimi F., Glagoleva E., Araviiskaia E. Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing. Dermatol Ther. 2020;33(6):e13976. https://doi.org/10.1111/dth.13976

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).